Introduction
Apoptosis, genetically programmed cell death, plays an important role in embryonogenesis, reparation and regeneration processes. 1 The disturbance of apoptosis in lymphocytes including autoreactive clones could induce autoantibody production. 2, 3 There are some literature data suggesting that abnormal regulation of apoptosis might be one of the important factors in pathogenesis of systemic lupus erythematosus, rheumatoid arthritis and systemic sclerosis (SSc). 4 Á 6 Cysteine-aspartic acid-specific proteases (caspases) appear to have important roles in apoptotic execution. 7, 8 Until now, three families of those enzymes, playing different roles in the cells, have been demonstrated: caspases regulating pro-inflammatory cytokine maturation, initiating caspases, and executive caspases.
It is widely accepted that proteolytic enzymes destroy structural and enzymatic cell proteins; however, their precise role has not been elucidated. Caspase 1 is also called interleukin-1b converting enzyme, pro-interleukin-18 and phospholipase A 2 converting enzyme. 9, 10 Literature data indicate that the aforementioned proteolytic enzyme, however, is not indispensable in apoptosis, and plays an important role in cytokine release and inflammation development. 9, 10 All the caspase producing cells, or at least the majority of them, have to have strong mechanisms preventing activation of these enzymes.
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Although apoptosis is based on genetically programmed changes in cells, there are some apoptosis regulating factors in the organisms. Some proteins from the tumour necrosis factor family such as myc and Fas (called also APO-1 or CD95) can trigger apoptosis. 12 Several factors could also inhibit programmed cell death: oncogen bcl-2, excessive amounts of soluble tumour necrosis factor-alpha receptor and antioxidants. 7 In the group of chronic connective tissue diseases, systemic sclerosis is characterized by dysregulation of the immune system and excessive accumulation of extracellular matrix in the skin and various internal organs. 13 It seems that imbalance between proapoptotic and anti-apoptotic factors could be responsible not only for immunological disturbances and inflammation, but for internal organ involvement in the course of systemic sclerosis as well, just like in systemic lupus erythematosus. 4 The aim of our study was to perform measurements of caspase 1 and sFas serum levels in 29 scleroderma patients in comparison with the control group and their correlation with duration of Raynaud's phenomenon, duration of skin involvement and its extent together with internal organ changes. 14 Because of the rapid disease progression, all the dSSc patients were on immunosuppressive regimen (50 mg cyclophosphamide daily and 20 mg prednison daily).
Materials and methods
Duration of Raynaud's phenomenon and skin sclerosis were evaluated in all the patients. The degree of skin sclerosis was assessed using the Total Skin Score according to Kahaleh et al. (0Á/66 points). 15 Four internal organs, the oesophagus, the cardiovascular system, the joint and bone system, and the lung, were evaluated by six specific tests: (1) oesophagal scintigraphy, (2) electrocardiography, (3) Doppler echocardiography, (4) X-ray feet and hand bone, (5) X-ray chest, and (6) lung spirometry. The letter was expressed in percentages of the required value: forced vital capacity (FVC), forced expiratory volume in 1 sec (FEV 1 ) and the ratio FEV 1 / FVC. Restrictive disturbances of the lungs were diagnosed when FVC was below 80% of the desired value, while the value of the ratio FEV 1 /FVC was elevated or within the normal range. Obstructing lesions were diagnosed when the value of FEV 1 was reduced, and mixed lesions when the reduction in the predicted values of both FVC and FEV 1 were similar. 16 Those parameters were not scored. Blood was collected in the morning into the pyrogen-free tubes and stored at Á/208C until further evaluated. Caspase 1 levels were measured in 17 patients (eight with dSSc and nine with lSSc) and sFas in 29 patients (15 with dSSc and 14 with lSSc). The control group consisted of 10 healthy persons (nine women and one man, aged 25 Á/64 years; mean age, 46.39/13.2 years).
Caspase 1 and sFas serum levels were evaluated by enzyme-linked immunoassay (ELISA) technique (Quantikine R&D Systems Inc., Minneapolis, USA). The detection sensitivity of caspase 1 ranged between 0.22 and 1.24 pg/ml, and the minimum detectable dose of sFas is typically less than 20 pg/ml.
All patients and individuals from the control group gave their informed consent to participate in our study according to the Bioethic Committee of Medical University of Lodz requirements.
Statistical analysis
The obtained results were expressed as mean, maximum, minimum, and median values together with standard deviation. Numerical variables distribution was assessed by ShapiroÁ/Wilk test. Mann Á/ Whitney, Cochran Á/Cox and two independent sample tests were employed for comparison of mean or median values. Correlation between numerical values was evaluated by Spearman range correlation coefficient, r. p B/0.05 was considered statistically significant.
Results
Characteristics of the patients are presented in Table 1 . Table 2 presents abnormalities and changes in internal organs observed in the examined group of patients.
It was demonstrated that mean caspase 1 levels were lower in SSc patients than in the control group (61.69/76.4 pg/ml and 212.49/246.2 pg/ml, respectively, at p 0/0.005). It was also observed that dSSc patients demonstrated higher caspase 1 levels than lSSc ones (89.79/87.1 pg/ml and 36.59/59.4 pg/ml, respectively, at p0/0.1). Mean serum sFas levels were higher in the patient group than in the healthy controls (3098.39/624.4 pg/ml and 1080.19/429.5 pg/ml, respectively, at p 0/0.00005). What is more, dSSc patients had higher sFas serum levels than the lSSc group (3239.39/483.2 pg/ml and 2947.29/735.3 pg/ml, respectively) ( Table 3) .
Statistical analysis with the Spearman range correlation coefficient demonstrated statistically significant, negative correlations between duration of Raynaud's phenomenon and sFas serum levels in systemic sclerosis patients as a whole group (r0/ Á/0.549, p0/0.002) and limited SSc patients (r0/ Á/0.672, p 0/0.009) ( Table 4) .
We analysed the relationship between serum concentrations of both parameters and extensiveness of skin involvement. We found positive correlations between serum levels of sFas (r0/0.365, p0/0.05) in systemic sclerosis patients as a whole group and Total Skin Score. In contrast, we observed negative correlation between caspase 1 (r 0/Á/0.711, p 0/0.04) and sFas (r 0/Á/0.097) serum levels and Total Skin Score in the diffuse SSc patient subgroup (Table 4) . We also analysed caspase 1 and sFas serum levels in comparison with organ involvement in systemic sclerosis patients. We observed significantly lower caspase 1 levels in lSSc patients who had more internal organs involved (r 0/Á/0.709, p 0/0.03).
Statistical analysis showed that the mean value of caspase 1 level was statistically significantly lower in limited SSc patients with pulmonary dysfunction than in those without these disturbances (p0/0.05). In the same group of systemic sclerosis patients, mean value of sFas was higher in the patients with joint and bone changes than without them (p0/0.02). 
Discussion
Literature data has reported disturbances in apoptosis in the development of systemic sclerosis. 17 Szpringer and Lutnicki pointed at considerable inflammatory changes of blood vessels and fibroblast proliferation that could result from either increased production of growth factors or decreased sensitivity of those cells towards apoptosis inducing factors. 17 Some experimental data suggest that serum catabolic enzymes may influence apoptosis extensivity. It is postulated that inflammatory processes in scleroderma may lead to increased collagen deposition in the tissues. It was demonstrated that caspase 1, caspase 4, caspase 5 and caspase 11 can trigger inflammatory processes. 18 To the best of our knowledge, there is no literature data on serum caspase level evaluation in systemic sclerosis patients. Our study demonstrated higher mean caspase 1 serum levels in the control group in comparison with systemic sclerosis patients. This observation could suggest that lower serum levels of this protease correlated with apoptosis inhibition in systemic sclerosis patients.
Until now, evaluation of skin lesion severity has been one of the very important parameters of disease activity. We found a strong, statistically significant correlation in diffuse SSc patients between more extensive skin involvement and lower caspase 1 levels. Perhaps this data could account for one of the factors responsible for fibrosis development because more severe apoptosis disturbances are observed in this group in comparison with less severe cases.
Teraki and Shiohara pointed out at the important role of caspase 1 in Fas-triggered apoptotic processes. 7 Caspase 1 activates effector protease caspase 3 in cysteine protease cascade. Caspase 1 plays an important role in cytokine release and induction of the inflammatory reaction. 19 It is suggested that lower caspase 1 levels can inhibit apoptosis in the initial stages of systemic sclerosis development, which in turn can activate T lymphocytes and B lymphocytes. Our data showed correlation between lower caspase 1 serum levels in patients with some internal organs involved. The statistically significant correlation was found only in limited SSc patients with pulmonary dysfunction diagnosed on spirometry. We had assumed that our treatment regimens did not influence caspase 1 levels. Both in patients on either immunosuppressive treatment or vasodilatators and vitamin E, caspase 1 levels were lower than in the control group.
Literature data point out the importance of sFas in apoptosis in the course of autoimmunological disorders. 20, 21 Higher sFas serum levels were demonstrated in patients with rheumatoid arthritis, systemic lupus erythematosus, mixed connective tissue disease, dermatomyositis-polymyositis and silicosis as well as in scleroderma, when comparing with the control groups. 3, 21 The results obtained by us also showed statistically significant higher sFas serum levels in scleroderma patients in comparison with the control group. Those differences seem to depend on the clinical presentation. Serum sFas levels were higher in the dSSc subgroup than in the lSSc one. We found strong correlations between shorter duration of Raynaud's phenomenon and higher sFas serum concentration. Soluble Fas levels also correlated with skin involvement severity. What is more, patients with joint and bone changes also presented increased sFas serum levels.
It could be assumed that, just like in systemic lupus erythematosus, also in scleroderma higher sFas serum levels may be regarded as a manifestation of some systemic changes. 3 The observed results are in agreement with the literature data demonstrating importance of sFas in apoptosis triggering in the course of autoimmune diseases. 22, 23 Increased sFas serum levels in systemic sclerosis patients may protect autoreactive T lymphocytes against apoptosis induced by the Fas ligand system. 21 Fas stimulation prevents intracellular calcium ions entrance, which is obligatory for lymphocyte T proliferation, differentiation and cytokine production. 4 Wetzig et al. demonstrated increased sFas serum levels in the group of 30 scleroderma patients in comparison with the controls. 24 There were no significant differences in this protein serum level between lSSc and dSSc patients. This research group concluded that sFas serum levels in scleroderma patients might be only a clinical marker of autoimmune disturbances in the course of this disease but not a reliable parameter of inflammatory process activity.
Our results showed that imbalance between caspase 1 and sFas serum levels could exert an inhibitory effect on apoptosis in patients with systemic sclerosis. Serum levels of caspase 1 and sFas correlated with skin involvement, sFas levels with bone and joint changes, and caspase 1 with pulmonary dysfunction.
